Summary
- Current Price
- As of today, ONC price is $347.48, down -2.40% on
- Current Price All-Time High
- ONC price is currently -18.54% below its historical high of $426.56 set on
- Market Cap
- ONC current market cap is $39B, up +25.66% over the past 365 days
- PE Ratio
- ONC current PE ratio is 61.06
- Revenue
- ONC current annual revenue is $5.36B, up +40.53% year-over-year
- Next Earnings
- The next earnings release for ONC is on
Profile
| Metric | Value |
|---|---|
| Full Name | BeOne Medicines AG |
| Ticker | NASDAQ: ONC |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Switzerland |
| IPO | |
| Indexes | Not included |
| Website | beonemedicines.com |
| Employees | 12,000 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $347.48 | |
| Price, 1D Change | -2.40% | |
| Market Cap | $39B | |
| - | ||
| PE Ratio | 61.06 | |
| Beta | 0.75 | |
| Revenue | $5.36B | |
| Revenue, 1Y Change | +40.53% | |
| EPS | $2.54 | |
| EPS, 1Y Change | +141.39% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | BGNE | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $2.54 | |
| EPS Estimate | $7.60 | N/A |
| EPS Est. Change | +199.61% | N/A |
| Revenue | $5.36B | |
| Revenue Estimate | $6.75B | N/A |
| Revenue Est. Change | +26.06% | N/A |
| Current Price | $347.48 | |
| Price Target | $430.00 | - |
| Price Tgt. Change | +23.75% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$5.69 | -$6.13 | -7.72% | |
| $3.33 | $2.54 | -23.74% | |
| $7.60 | N/A | +199.61% | |
| $10.28 | N/A | +305.55% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.71B | $3.81B | +2.76% | |
| $5.30B | $5.36B | +1.12% | |
| $6.75B | N/A | +26.06% | |
| $7.70B | N/A | +43.75% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +12.20% | |
| Price, 3Y | +70.22% | |
| Market Cap, 1Y | +25.66% | |
| Market Cap, 3Y | +99.25% | |
| Revenue, 1Y | +40.53% | |
| Revenue, 3Y | +278.35% | |
| EPS, 1Y | +141.39% | |
| EPS, 3Y | +113.05% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $347.48 | |
| SMA 200 | $315.14 | |
| SMA 50 | $302.51 | |
| EMA 200 | $305.69 | |
| EMA 50 | $315.19 | |
| MACD | $13.19 | |
| Beta | 0.75 | |
| ATR | $9.71 | |
| 14-Day RSI | 65.30 | |
| 10-Day Volatility | 39.68% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $5.36B | |
| EPS | $2.54 | |
| Gross Profit | $0.00 | |
| Gross Margin | 85.28% | |
| Operating Income | $448.32M | |
| Operating Margin | 8.37% | |
| Net Income | $287.69M | |
| Net Margin | 5.37% | |
| EBITDA | $590.38M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.46 | |
| 3.41 | ||
| 3.08 | ||
| - | ||
| 6 | ||
| 6.02 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 61.06 | |
| 6.40 | ||
| 8.24 | ||
| 33.40 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $4.01B | |
| $4.59B | ||
| $8.23B | ||
| $6.23B | ||
| $3.84B | ||
| $1.83B | ||
| Total Debt | $2.00B | |
| $134.71M | ||
| $479.04M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $5.07B | ||
| $4.12B | ||
| $788.63M | ||
| $0.00 | ||
| $142.06M | ||
| $0.00 | ||
| $130.26M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $1.13B | ||
| -$276.89M | ||
| $1.06B | ||
| Capex | $206.38M | |
| $924.18M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Truist Securities | → | |
| TD Cowen | → | |
| RBC Capital | → | |
| Guggenheim | → | |
| Citizens | → | |
| Barclays | → | |
| JP Morgan | → | |
| Barclays | → | |
| Jefferies | → | |
| Truist Securities | → |
Analyst sentiment
Institutional ownership
Screeners with ONC
FAQ
- What is the ticker symbol for BeOne Medicines AG?
- The ticker symbol for BeOne Medicines AG is NASDAQ:ONC
- Does BeOne Medicines AG pay dividends?
- No, BeOne Medicines AG does not pay dividends
- What sector is BeOne Medicines AG in?
- BeOne Medicines AG is in the Healthcare sector
- What industry is BeOne Medicines AG in?
- BeOne Medicines AG is in the Biotechnology industry
- What country is BeOne Medicines AG based in?
- BeOne Medicines AG is headquartered in Switzerland
- When did BeOne Medicines AG go public?
- BeOne Medicines AG initial public offering (IPO) was on February 3, 2016
- Is BeOne Medicines AG in the S&P 500?
- No, BeOne Medicines AG is not included in the S&P 500 index
- Is BeOne Medicines AG in the NASDAQ 100?
- No, BeOne Medicines AG is not included in the NASDAQ 100 index
- Is BeOne Medicines AG in the Dow Jones?
- No, BeOne Medicines AG is not included in the Dow Jones index
- When was BeOne Medicines AG last earnings report?
- BeOne Medicines AG's most recent earnings report was on August 5, 2026
- When does BeOne Medicines AG report earnings?
- The next expected earnings date for BeOne Medicines AG is November 5, 2026
Data Sources & References
- ONC Official Website beonemedicines.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index.htm
- ONC Profile on Yahoo Finance finance.yahoo.com/quote/ONC
- ONC Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/onc